$CORT

Vieira Roberto Wandenkolk (President, Oncology) sold 8,333 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.10 ($114.52–$116.58, $0.97M total) across 3 trades on 2026-10-02 under a Rule 10b5-1 trading plan.

Lyon Joseph Douglas (See Remarks) sold 10,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.07 ($115.40–$116.54, $1.16M total) across 3 trades over 2026-10-01 to 2026-10-02 under a Rule 10b5-1 trading plan.

Maduck Sean (See Remarks) sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.26 ($115.54–$116.55, $2.91M total) across 3 trades over 2026-10-01 to 2026-10-02 under a Rule 10b5-1 trading plan.

JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC) added 171 positions on Monday, deploying $161.2 million in net purchases. Its largest buys were Corcept Therapeutics (CORT) at $3.3 million, Elastic NV (ESTC) at $2.2 million, and SentinelOne (S) at $2.2 million. BBSC holds 804 stocks with a 0.09% expense ratio and a 14.66% year-to-date return.

Blue Orca and Iceberg Research published reports on EquipmentShare.com (EQPT) and Deep Fission (FISN), alleging financial and operational issues. EquipmentShare disputes the claims. Viceroy and Scorpion Capital raised concerns about Blue Moon Metals (BMM) and Twist Bioscience (TWST). Several companies, including Corcept Therapeutics (CORT), Nutanix (NTNX), and Zscaler (ZS), reported executive departures. Michael Burry warned of $3 trillion in AI-related commitments across major tech firms.

CORCEPT THERAPEUTICS INC (CORT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Announces Planned Leadership Transition Sean Maduck to Retire; Justin Gunn Appointed President, Endocrinology REDWOOD CITY, Calif. – September 23, 2026 – C

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

Corcept Therapeutics (CORT) has been added to the S&P 400 index. The company's stock has seen a 5-day change of -3.98%, a 1st Jan change of -2.22%, and a year-to-date increase of +216.93%.

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

Corcept Therapeutics (CORT) announced the European Medicines Agency's CHMP recommended EU approval for relacorilant, combined with nab-paclitaxel, to treat platinum-resistant ovarian cancer. The recommendation follows positive Phase 2 and Phase 3 trial results showing improved survival rates. The EC will decide by Q4 2026. Relacorilant is already FDA-approved in the U.S. for the same indication.